Team Portfolio Raise Essays

F4/Droia Ventures/Activity

Droia Ventures Activity

Every public signal F4 has attached to this firm, with sources and cross-entity links.

Types

Time range

Exit

BioMarin agreed to acquire portfolio company Alesta Therapeutics for $275M upfront.

Alesta Therapeutics

Alesta Therapeutics Droia Ventures

droiaventures.comAUG 18, 2026

AUG 18, 2026

Droia Ventures | Activity | F4

Investment

Vaderis raised an oversubscribed $152M Series B and began the Phase 3 HEROIC study.

Vaderis Therapeutics

Vaderis Therapeutics Droia Ventures

droiaventures.comAUG 11, 2026

AUG 11, 2026

Exit

Jazz Pharmaceuticals agreed to acquire portfolio company Actio Biosciences for $820M.

Actio Biosciences

Actio Biosciences Droia Ventures

droiaventures.comAUG 10, 2026

AUG 10, 2026

New Fund

Closed its third fund, Droia Genetic Disease, at EUR 220M and added George Golumbeski as partner.

Droia Genetic Disease fund

droiaventures.comMAY 11, 2021

MAY 11, 2021